- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Considerations & Factors For Switching & Augmenting Medications For Major Depressive Disorder

About This Event
Considerations & Factors For Switching & Augmenting Medications For Major Depressive Disorder
This is a Live Event for PsychU Members in West Virginia.
In this presentation, the objectives are to:
- To discuss treatment challenges and guidelines for treating major depressive disorder (MDD)
- To consider recommendations from the literature regarding making a treatment change for patients with partial or non-response to current treatment
- To understand considerations from the literature regarding switch vs. augmentation as a treatment strategy for patients with partial or non-response
- To explore physician determinants of use of antipsychotic treatment augmentation for patients with MDD
21 at the Frederick

Lindsey Wright, PharmD
Medical Science Liaison
Speaker Lindsey Wright, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Related Events
Registration
PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients. NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.